Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $73.8 million.

  • Pharming Group N.V's Total Current Liabilities rose 10.11% to $87.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.9 million, marking a year-over-year increase of 10.11%. This contributed to the annual value of $73.8 million for FY2024, which is 5.34% down from last year.
  • Latest data reveals that Pharming Group N.V reported Total Current Liabilities of $73.8 million as of FY2024, which was down 5.34% from $78.0 million recorded in FY2023.
  • Pharming Group N.V's Total Current Liabilities' 5-year high stood at $78.0 million during FY2023, with a 5-year trough of $46.8 million in FY2021.
  • For the 3-year period, Pharming Group N.V's Total Current Liabilities averaged around $70.5 million, with its median value being $73.8 million (2024).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 39.14% in 2021, then soared by 30.60% in 2023.
  • Over the past 5 years, Pharming Group N.V's Total Current Liabilities (Yearly) stood at $76.8 million in 2020, then crashed by 39.14% to $46.8 million in 2021, then increased by 27.64% to $59.7 million in 2022, then skyrocketed by 30.60% to $78.0 million in 2023, then declined by 5.34% to $73.8 million in 2024.